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Abstract: Background: External beam radiotherapy is delivered using a 
uniform fractionation schedule for localised prostate tumours, 
individualising fractionation according to tumour biology could improve 
outcomes. Additionally recurrence rates following radiotherapy vary 
considerably, better prognostic markers could improve treatment 
stratification. This study assessed if the cellular proliferation marker 
Ki67 provides prognostic information and predicts response to 
radiotherapy fractionation in patients participating in ****, a 
randomised trial of three radiotherapy fractionation schedules (74Gy/37f 
vs 60Gy/20f vs 57Gy/19f). 
 
Methods: A matched case:control study design was used, patients with 
biochemical/clinical failure >2 years after radiotherapy (BCR) were 
matched 1:1 to patients without recurrence using established prognostic 
factors (Gleason score, PSA, tumour-stage) and fractionation schedule. 
Immunohistochemistry was used to stain diagnostic biopsy specimens for 
Ki67, which were scored using the unweighted global method. Conditional 
logistic regression models estimated the prognostic value of mean and 
maximum Ki67 scores on BCR risk. Biomarker-fractionation interaction 
terms determined whether Ki67 was predictive of BCR by fractionation.  
 
Results: Using 173 matched pairs, the median for mean and maximum Ki67 
scores were 6.6% (IQR:3.9-9.8) and 11.0% (IQR:7.0-15.0) respectively. 
Both scores were significant predictors of BCR in models adjusted for 
established prognostic factors. Conditioning on matching variables and 
age, the odds of BCR was estimated to increase by 9% per 1% increase in 
mean Ki67 score (OR=1.09, 95%CI:1.04-1.15,p=0.001).  Interaction terms 
between Ki67 and fractionation schedules were not statistically 
significant. 
  
Conclusions: Diagnostic Ki67 did not predict BCR according to 
fractionation schedule in ****, however it was a strong independent 
prognostic factor for BCR. 
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Dear Professor Zietman 
Re: Ki67 is an independent predictor of recurrence in the largest randomised trial of 
3 radiation fractionation schedules in localised prostate cancer 
We are very grateful for your consideration of the above manuscript for publication in 
the IJROBP. This manuscript evaluates the well-established proliferation marker 
Ki67 in localised prostate cancer, for the first time using methodology that has been 
internationally validated and accounts for spatial intra-tumoural heterogeneity.  The 
manuscript assesses both the association of Ki67 with overall risk of recurrence after 
radiotherapy, and risk of recurrence according to radiotherapy fractionation 
schedule.   
The CHHiP trial is the largest randomised trial in localised prostate cancer to 
compare different radiation schedules reported to date.  It therefore represents a 
unique opportunity to research biomarkers related to personalised fractionation.  Our 
results offer important reassurance that shorter, more convenient hypofractionated 
schedules are not detrimental in tumours with relatively high proliferation.  
In addition, Ki67 predicted recurrence independently of established prognostic 
factors including Gleason score. This routinely available and affordable test could 
therefore aid treatment stratification in patients with localised prostate cancer, for 
example by intensification of androgen deprivation treatment such as with 
abiraterone or docetaxel, especially as highly proliferative tumours tend to respond 
better to cytotoxic chemotherapy. 
Thank you very much for your kind consideration of this manuscript that we believe 
has important translational relevance and will be of interest to your readership. 
Kind regards 
Dr Navita Somaiah 
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Re: Ki67 is an independent predictor of recurrence in the largest randomised trial of 
3 radiation fractionation schedules in localised prostate cancer 
Thank you for your email dated 24.12.2017. We have uploaded the missing tables 
and apologise for the omission. 
As no changes have been made to the actual blinded manuscript, we have uploaded 
two copies without tracked changes (as tracked and clean versions required by the 
system. 
Kind regards 
Dr Navita Somaiah 
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Summary 
Radiotherapy is delivered using uniform fractionation for localised prostate tumours 
despite varying recurrence rates. Biomarkers to guide treatment stratification and 
predict fraction size sensitivity are needed. This study evaluated Ki67 in localised 
prostate cancer, for the first time using an internationally validated methodology 
accounting for intra-tumoural heterogeneity. Ki67 did not predict recurrence 
according to fractionation, providing reassurance that hypofractionated schedules 
can be safely administered in highly proliferative tumours. Ki67 predicted 
biochemical/clinical recurrence independently of established prognostic factors 
including Gleason score. 
*Summary
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Ki67 is an independent predictor of recurrence in the largest randomised trial 
of 3 radiation fractionation schedules in localised prostate cancer  
 
Abstract 
Background: External beam radiotherapy is delivered using a uniform fractionation 
schedule for localised prostate tumours, individualising fractionation according to 
tumour biology could improve outcomes. Additionally recurrence rates following 
radiotherapy vary considerably, better prognostic markers could improve treatment 
stratification. This study assessed if the cellular proliferation marker Ki67 provides 
prognostic information and predicts response to radiotherapy fractionation in patients 
participating in ”, a randomised trial of three radiotherapy fractionation schedules 
(74Gy/37f vs 60Gy/20f vs 57Gy/19f). 
Methods: A matched case:control study design was used, patients with 
biochemical/clinical failure >2 years after radiotherapy (BCR) were matched 1:1 to 
patients without recurrence using established prognostic factors (Gleason score, 
PSA, tumour-stage) and fractionation schedule. Immunohistochemistry was used to 
stain diagnostic biopsy specimens for Ki67, which were scored using the unweighted 
global method. Conditional logistic regression models estimated the prognostic value 
of mean and maximum Ki67 scores on BCR risk. Biomarker-fractionation interaction 
terms determined whether Ki67 was predictive of BCR by fractionation.  
Results: Using 173 matched pairs, the median for mean and maximum Ki67 scores 
were 6.6% (IQR:3.9-9.8) and 11.0% (IQR:7.0-15.0) respectively. Both scores were 
significant predictors of BCR in models adjusted for established prognostic factors. 
*BLINDED Revised Manuscript (Changes Highlighted)
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Conditioning on matching variables and age, the odds of BCR was estimated to 
increase by 9% per 1% increase in mean Ki67 score (OR=1.09, 95%CI:1.04–
1.15,p=0.001).  Interaction terms between Ki67 and fractionation schedules were not 
statistically significant.  
Conclusions: Diagnostic Ki67 did not predict BCR according to fractionation 
schedule in ”, however it was a strong independent prognostic factor for BCR. 
 
Keywords: radiation fractionation, Ki67, prediction of recurrence, prostate cancer 
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Introduction 
Prostate cancer (PCa) is the second most common cancer worldwide for 
males, more than 1.11 million new cases were diagnosed in 2012 [1]. In the 
developed world, increased PSA testing means that most patients are diagnosed 
with localised disease, for which external beam radiotherapy (EBRT), brachytherapy 
and prostatectomy are important radical treatment options.    
Recurrence rates following EBRT for localised PCa vary considerably from 
approximately 10% to 40-50% [2,3]. Recurrences are inadequately predicted using 
current prognostic algorithms that incorporate Gleason grade, T-stage and 
presenting PSA. Identification of prognostic biomarkers to aid treatment stratification 
would therefore be clinically useful. 
In addition, EBRT is delivered using a uniform fractionation schedule for all 
localised PCa i.e. a “one size fits all approach”. This is despite a wide variation in the 
biology of localised PCa [4], including proliferation rate [5]. A personalised approach 
to fractionation therefore offers considerable potential to improve therapeutic 
outcomes. Biomarkers predicting sensitivity to RT fraction size have recently been 
identified as a key area for radiobiological research [6].   
There is a tight inverse association between the proliferative indices of normal 
tissues and fractionation sensitivity. Tissues with high proliferation indices such as 
gastro-intestinal mucosa and epidermis, are insensitive to fraction size. In contrast 
late-reacting normal tissues, such as kidney, have low proliferative indices and are 
very sensitive to fraction size [7,8]. This study tests the hypothesis that the same 
association between proliferative indices and fractionation sensitivity in normal 
tissues extends to localised PCa. 
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The “ trial (”) randomly assigned 3216 men to conventional fractionation (74 
Gy in 37 fractions over 7.4 weeks) or one of two hypofractionated schedules (60 Gy 
in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) [3]. Trans-“ is 
the main translational sub-study within ”, tissue blocks from over 2000 patients have 
been collected. It provides an excellent opportunity to test the above hypothesis. The 
expectation is that highly proliferative cancers will show insensitivity to fraction size 
and be more likely to relapse after the reduced total dose in hypofractionated (>2Gy) 
schedules. In contrast slowly proliferating tumours are expected to be sensitive to 
fraction size hence more likely to relapse after conventional fractionation (2Gy) 
schedules [7]. 
Materials and Methods 
Study design 
A matched case:control methodology was used to select study participants. 
The study was approved by the London Multi-centre Research Ethics Committee 
(04/MRE02/10) and the local ethics committees of all participating centres. Patients 
experiencing recurrence (cases) were matched 1:1 to patients without recurrence 
(controls). Matching criteria included fractionation schedule (74Gy/37f, 60Gy/20f or 
57Gy/19f) and established prognostic factors including PSA (<10/10-20/>20ng/ml), 
Gleason grade (3+3/3+4/4+3/≥4+4) and T-stage (T1/T2/T3). All tissue samples were 
centrally reviewed by a specialist uropathologist (CMC), including assignment of 
Gleason grade according to recent ISUP and WHO recommendations [9,10]. The 
centrally assigned Gleason grade was used for matching. 
Immunohistochemistry staining and scoring 
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Full-face sections from the diagnostic biopsy blocks were used for 
immunohistochemistry staining. This decision followed a pilot study that 
demonstrated construction of tissue microarray, using the checkerboard technique 
[11], resulted in inadequate tumour cellularity (tables S1 and S2). 
Immunohistochemistry staining methods are outlined in the supplementary appendix. 
All slides were scored using bright field microscopy by two independent investigators 
blinded to recurrence status and fractionation schedule. The CK5/6 basal marker 
distinguished pre-invasive from invasive disease. Prostatic intra-epithelial neoplasia 
and intra-ductal carcinoma were not scored. A minimum of 100 tumour cells were 
required to score each case.  
The unweighted global assessment of Ki67 developed by the International 
Ki67 Working Group was used to score all prostate biopsies [12,13]. This includes 
assessment of intra-tumoural spatial heterogeneity, which is well-recognised in 
localised PCa [14]. The global assessment has met pre-specified criteria for scoring 
reproducibility in an international phase III study using core biopsies of breast 
tumours [13]. It involves counting 100 tumour cells in up to 4 high power fields to 
derive a mean Ki67 score (figure 1). Fields are chosen following an assessment of 
overall heterogeneity in staining. The final mean Ki67 score consisted of the average 
of the two scoring investigator’s mean Ki67 scores for each case. Maximum Ki67 
was assessed by one investigator and consisted of the highest scoring individual 
field (figure 1). This was included because the highest proliferative tumour area may 
be important for radiotherapy response.  
All cases with a discrepancy in initial mean Ki67 score >10% were re-scored 
[15]. Further rescores were carried out if the discrepancy remained >10%.  
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Study endpoints 
Mean and maximum Ki67 scores were evaluated. Recurrence was defined as 
patients with biochemical [16] or clinical failure after radiotherapy (BCR). Patients 
experiencing BCR within two years of radiotherapy commencement were excluded 
because they are more likely to have developed distant metastases than local 
recurrence due to radiotherapy failure [2]. All data pertaining to recurrence was taken 
from a “ data snapshot (11/09/2015) where median follow up was 62.4 months (IQR: 
53.9-77.0). Non-recurrence was defined in patients with no evidence of BCR alive at 
the data snapshot.  
Statistical analysis 
Agreement in Ki67 scores between the two scoring investigators was 
assessed using Bland-Altman plots to measure the difference between the scores 
versus the mean of the mean Ki67 scores [17]. The concordance correlation 
coefficient was used to quantify agreement. The difference in the mean Ki67 scores 
(mean and maximum) between the matched cases and controls by fractionation 
schedule was compared using paired t-tests. 
Both Ki67 endpoints were analysed as continuous variables to maximise 
statistical power [18]. Multivariable conditional logistic regression models were fitted 
to estimate the prognostic value of Ki67 on the risk of BCR, using the entire Trans-“ 
case-control study cohort. To determine whether Ki67 predicted BCR by 
fractionation, a biomarker-fractionation interaction term was included. Three 
comparisons were undertaken to avoid confounding by different recurrence rates 
across trial arms (74Gy/37f versus 60Gy/20f, 74y/37f versus 57Gy/19f and 60Gy/20f 
versus 57Gy/19f). Based on an alpha of 0.017, we estimated a power of 75.5%, 
7 
 
74.8% and 70.0% to detect an interaction between each fractionation schedule and 
Ki67 respectively (table S4).  
All statistical analysis was conducted using STATAv13.0 and R 
(version:i3863.3.3). 
Results 
Patient characteristics 
437 cases were assessed by both scoring investigators. Ki67 scores were 
provided by both investigators in 400 cases, in 37 cases there was insufficient 
tumour present. The final matched dataset comprised 173 patients with BCR after 
start of radiotherapy (cases) and 173 patients without recurrence (controls). 
Matching was achieved to 100% of relevant criteria in all cases analysed. 54 patients 
were excluded as they did not have an appropriate match, these were usually 
controls with no available matching case. Table 1 shows the distribution of the 
matching variables and age for the controls and cases.  
Agreement in Ki67 scores  
Of the total of 400 cases scored by both investigators, in 12 (3.0%) cases the 
difference in mean Ki67 between the two scoring investigators was ≥10% (IQR:11.8-
15.1%). These were re-scored by both scoring investigators. All re-scores were 
within the required <10% discrepancy.  
Scatter plots comparing each scoring investigator’s final scores, and Bland-
Altman plots comparing the difference in final score versus the mean Ki67 are shown 
in figure 2 (original scores figure S1). The Bland-Altman plots indicate that the 
difference in score tended to increase as the mean Ki67 score increased. The overall 
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agreement was considered to be good with a concordance correlation coefficient of 
0.74 (95% CI: 0.70-0.78, p<0.001) for the final scores. For the original scores prior to 
rescore, the concordance correlation coefficient was 0.63 (95% CI: 0.58-0.68, 
p<0.001). 
Prediction of biochemical/clinical recurrence  
Multivariable conditional logistic regression models using the entire Trans-“ 
case-control study sample showed that both mean Ki67 and maximum Ki67 were 
statistically significant predictors of BCR (tables 2 and S3). For each unit increase in 
mean Ki67 the odds of BCR is estimated to increase by 9% (OR=1.09, 95% CI: 1.04-
1.15, p=0.001) having adjusted for matching variables and age. It is clinically 
relevant that the prediction of recurrence by mean Ki67 is independent of Gleason 
grade. The lack of correlation between mean Ki67 and Gleason grade is also 
displayed in the box and whisker plot (figure 3). For the maximum Ki67, the odds of 
BCR were estimated to increase by 5% for each unit increase in the maximum Ki67 
score (OR=1.05, 95% CI: 1.01-1.09, p=0.006) in the multivariable model. 
Prediction of fraction sensitivity 
The interaction tests between either mean or maximum Ki67 and fractionation 
schedule was not statistically significant for all comparisons (table 3 and S3). The 
distribution of mean and maximum Ki67 scores according to fractionation schedule 
and recurrence status, including a statistical comparison of the difference between 
cases and controls within fractionation arms is shown in figure S2.  
Discussion 
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This study measures Ki67 staining indices in localised PCa treated with 
different radiotherapy fractionation schedules. It indicates that the global unweighted 
method for scoring Ki67 can be used with good agreement between independent 
scoring investigators without prior experience of this method. To our knowledge this 
is the first report using the global unweighted method in PCa. However it is an 
established method to aid treatment stratification in breast cancer [19] where Ki67 is 
used clinically to distinguish between low proliferation luminal A and higher 
proliferative luminal B breast cancer subtypes [20].  
The statistically significant association between mean Ki67 and prediction of 
BCR has potential clinical application. Our results require external validation in 
additional patient cohorts, with particular attention to the spectrum of Ki67 
expression in different risk groups and a rigorous assessment of scoring 
concordance in prostate biopsies across different centres. Patients with high mean 
Ki67 but otherwise lower risk factors could be recommended longer or more 
intensive androgen deprivation (ADT), with possible addition of Docetaxel or 
abiraterone [21]. Patients with low mean Ki67 could be reassured that they are likely 
to have a good prognosis and might be candidates for studies of reduced ADT. This 
study suggests that Ki67 is of maximal predictive benefit when used as a continuous 
variable, this method of stratification is used effectively in the clinic for Ki67, and 
other expression profiling-based algorithms [19,22].  
Our exclusion of patients with BCR less than two years after radiotherapy 
means the estimates of the predictive value of Ki67 are likely to be conservative. 
Maximum Ki67 was also a statistically significant predictor of BCR which is worthy of 
further study as a single field assessment of 100 cells is quicker than 4 fields for 
mean Ki67.  
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The apparent lack of interaction between Ki67 and fractionation schedule also 
has clinical implications. The range of proliferative indices seen indicates that, the 
predominantly intermediate risk, PCa included in the trial are usually slowly 
proliferative. However when including those cancers showing relatively high 
proliferation rates, there was no suggestion of a detriment using hypofractionated 
radiotherapy schedules giving 3Gy/fraction. Other tumour types encompass wider 
ranges in proliferation and show higher average proliferation [7]. Our results should 
not be interpreted as demonstrating a general lack of association between 
proliferation and fraction sensitivity. An important confounding factor may be the 
complex interplay between fraction sensitivity and overall treatment time [23]. 
Additionally we acknowledge that the statistical power of tests of interaction are low, 
and that a relatively small proportion of high risk PCa were included in ”. 
3112 of 3216 (96.7%) of patients recruited to “ were treated with ADT from 
just after their diagnostic biopsy until completion of radiotherapy. ADT may modulate 
fraction sensitivity as it can markedly reduce proliferation and affect repair of double 
stranded DNA breaks (dsDNA) [24]. ADT can also inhibit the cell cycle at the G1/S 
checkpoint as part of induction of senescence [25,26]. This inhibition could restrict 
use of dsDNA repair pathway homologous recombination, which operates 
exclusively in S and G2 and is thought to mediate resistance to fraction sensitivity 
[27,28]. Cells would instead rely on error prone non-homologous end joining which 
operates throughout the cell cycle and is important for fraction sensitivity [27,28]. In 
the PROFIT trial of radiotherapy fractionation, men did not receive ADT and 
outcomes were similar to “ [29]. This suggests that ADT does not have a major 
impact on average fraction sensitivity in PCa, however ADT may have confounded 
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the interaction between proliferation and BCR according to fractionation schedule in 
our study.   
Our results are supported by a recent report by Pollack et al [30]. In this, a 
single cut-point (11.3%) was used to score Ki67, fractionation schedules differed to 
our study and there were fewer failure events. However Ki67 demonstrated 
independent prediction of prognosis and did not predict fraction sensitivity. It is 
relevant that Ki67 immunohistochemistry is routinely available and affordable for 
most pathology laboratories, and automated scoring algorithms are showing 
potential clinical applicability [31].  
This study assessing Ki67 in patients treated with different radiotherapy 
fractionation schedules reaches two conclusions. Firstly, it does not suggest that 
there is a detriment to using hypofractionated radiotherapy schedules in PCa 
showing relatively high proliferation. Secondly, Ki67 is a highly statistically significant 
biomarker predicting recurrence, independent of established prognostic factors. As 
localised PCa shows diverse clinical outcomes, Ki67 has a potential clinical 
application to guide treatment stratification. 
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Titles an legends to figures 
 
Figure 1: Scoring Ki67 using the global unweighted methoda.  
aThis case contained 50% high proliferation tumour and 50% low proliferation tumour 
therefore high power fields were selected for 2 highly proliferative areas and 2 low 
proliferative areas. In this case the number of positive staining cells were: field 1 
39/100, field 2 33/100, field 3 5/100 and field 4 5/100. This gives a mean Ki67 score 
of 20.5% and a maximum Ki67 score of 39%. 
Figure 2: A: Scatterplot showing concordance in final mean Ki67 between 
independent scoring investigators, B: Brand-Altman plot showing difference in final 
scores between investigator 1 and investigator 2 versus means scores. 
Figure 3: Box and whisker plot showing relationship between Mean Ki67 and 
Gleason grade group.  
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Ki67 is an independent predictor of recurrence in the largest randomised trial 
of 3 radiation fractionation schedules in localised prostate cancer  
 
Abstract 
Background: External beam radiotherapy is delivered using a uniform fractionation 
schedule for localised prostate tumours, individualising fractionation according to 
tumour biology could improve outcomes. Additionally recurrence rates following 
radiotherapy vary considerably, better prognostic markers could improve treatment 
stratification. This study assessed if the cellular proliferation marker Ki67 provides 
prognostic information and predicts response to radiotherapy fractionation in patients 
participating in ”, a randomised trial of three radiotherapy fractionation schedules 
(74Gy/37f vs 60Gy/20f vs 57Gy/19f). 
Methods: A matched case:control study design was used, patients with 
biochemical/clinical failure >2 years after radiotherapy (BCR) were matched 1:1 to 
patients without recurrence using established prognostic factors (Gleason score, 
PSA, tumour-stage) and fractionation schedule. Immunohistochemistry was used to 
stain diagnostic biopsy specimens for Ki67, which were scored using the unweighted 
global method. Conditional logistic regression models estimated the prognostic value 
of mean and maximum Ki67 scores on BCR risk. Biomarker-fractionation interaction 
terms determined whether Ki67 was predictive of BCR by fractionation.  
Results: Using 173 matched pairs, the median for mean and maximum Ki67 scores 
were 6.6% (IQR:3.9-9.8) and 11.0% (IQR:7.0-15.0) respectively. Both scores were 
significant predictors of BCR in models adjusted for established prognostic factors. 
*BLINDED Revised Manuscript (Unmarked)
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Conditioning on matching variables and age, the odds of BCR was estimated to 
increase by 9% per 1% increase in mean Ki67 score (OR=1.09, 95%CI:1.04–
1.15,p=0.001).  Interaction terms between Ki67 and fractionation schedules were not 
statistically significant.  
Conclusions: Diagnostic Ki67 did not predict BCR according to fractionation 
schedule in ”, however it was a strong independent prognostic factor for BCR. 
 
Keywords: radiation fractionation, Ki67, prediction of recurrence, prostate cancer 
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Introduction 
Prostate cancer (PCa) is the second most common cancer worldwide for 
males, more than 1.11 million new cases were diagnosed in 2012 [1]. In the 
developed world, increased PSA testing means that most patients are diagnosed 
with localised disease, for which external beam radiotherapy (EBRT), brachytherapy 
and prostatectomy are important radical treatment options.    
Recurrence rates following EBRT for localised PCa vary considerably from 
approximately 10% to 40-50% [2,3]. Recurrences are inadequately predicted using 
current prognostic algorithms that incorporate Gleason grade, T-stage and 
presenting PSA. Identification of prognostic biomarkers to aid treatment stratification 
would therefore be clinically useful. 
In addition, EBRT is delivered using a uniform fractionation schedule for all 
localised PCa i.e. a “one size fits all approach”. This is despite a wide variation in the 
biology of localised PCa [4], including proliferation rate [5]. A personalised approach 
to fractionation therefore offers considerable potential to improve therapeutic 
outcomes. Biomarkers predicting sensitivity to RT fraction size have recently been 
identified as a key area for radiobiological research [6].   
There is a tight inverse association between the proliferative indices of normal 
tissues and fractionation sensitivity. Tissues with high proliferation indices such as 
gastro-intestinal mucosa and epidermis, are insensitive to fraction size. In contrast 
late-reacting normal tissues, such as kidney, have low proliferative indices and are 
very sensitive to fraction size [7,8]. This study tests the hypothesis that the same 
association between proliferative indices and fractionation sensitivity in normal 
tissues extends to localised PCa. 
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The “ trial (”) randomly assigned 3216 men to conventional fractionation (74 
Gy in 37 fractions over 7.4 weeks) or one of two hypofractionated schedules (60 Gy 
in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) [3]. Trans-“ is 
the main translational sub-study within ”, tissue blocks from over 2000 patients have 
been collected. It provides an excellent opportunity to test the above hypothesis. The 
expectation is that highly proliferative cancers will show insensitivity to fraction size 
and be more likely to relapse after the reduced total dose in hypofractionated (>2Gy) 
schedules. In contrast slowly proliferating tumours are expected to be sensitive to 
fraction size hence more likely to relapse after conventional fractionation (2Gy) 
schedules [7]. 
Materials and Methods 
Study design 
A matched case:control methodology was used to select study participants. 
The study was approved by the London Multi-centre Research Ethics Committee 
(04/MRE02/10) and the local ethics committees of all participating centres. Patients 
experiencing recurrence (cases) were matched 1:1 to patients without recurrence 
(controls). Matching criteria included fractionation schedule (74Gy/37f, 60Gy/20f or 
57Gy/19f) and established prognostic factors including PSA (<10/10-20/>20ng/ml), 
Gleason grade (3+3/3+4/4+3/≥4+4) and T-stage (T1/T2/T3). All tissue samples were 
centrally reviewed by a specialist uropathologist (CMC), including assignment of 
Gleason grade according to recent ISUP and WHO recommendations [9,10]. The 
centrally assigned Gleason grade was used for matching. 
Immunohistochemistry staining and scoring 
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Full-face sections from the diagnostic biopsy blocks were used for 
immunohistochemistry staining. This decision followed a pilot study that 
demonstrated construction of tissue microarray, using the checkerboard technique 
[11], resulted in inadequate tumour cellularity (tables S1 and S2). 
Immunohistochemistry staining methods are outlined in the supplementary appendix. 
All slides were scored using bright field microscopy by two independent investigators 
blinded to recurrence status and fractionation schedule. The CK5/6 basal marker 
distinguished pre-invasive from invasive disease. Prostatic intra-epithelial neoplasia 
and intra-ductal carcinoma were not scored. A minimum of 100 tumour cells were 
required to score each case.  
The unweighted global assessment of Ki67 developed by the International 
Ki67 Working Group was used to score all prostate biopsies [12,13]. This includes 
assessment of intra-tumoural spatial heterogeneity, which is well-recognised in 
localised PCa [14]. The global assessment has met pre-specified criteria for scoring 
reproducibility in an international phase III study using core biopsies of breast 
tumours [13]. It involves counting 100 tumour cells in up to 4 high power fields to 
derive a mean Ki67 score (figure 1). Fields are chosen following an assessment of 
overall heterogeneity in staining. The final mean Ki67 score consisted of the average 
of the two scoring investigator’s mean Ki67 scores for each case. Maximum Ki67 
was assessed by one investigator and consisted of the highest scoring individual 
field (figure 1). This was included because the highest proliferative tumour area may 
be important for radiotherapy response.  
All cases with a discrepancy in initial mean Ki67 score >10% were re-scored 
[15]. Further rescores were carried out if the discrepancy remained >10%.  
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Study endpoints 
Mean and maximum Ki67 scores were evaluated. Recurrence was defined as 
patients with biochemical [16] or clinical failure after radiotherapy (BCR). Patients 
experiencing BCR within two years of radiotherapy commencement were excluded 
because they are more likely to have developed distant metastases than local 
recurrence due to radiotherapy failure [2]. All data pertaining to recurrence was taken 
from a “ data snapshot (11/09/2015) where median follow up was 62.4 months (IQR: 
53.9-77.0). Non-recurrence was defined in patients with no evidence of BCR alive at 
the data snapshot.  
Statistical analysis 
Agreement in Ki67 scores between the two scoring investigators was 
assessed using Bland-Altman plots to measure the difference between the scores 
versus the mean of the mean Ki67 scores [17]. The concordance correlation 
coefficient was used to quantify agreement. The difference in the mean Ki67 scores 
(mean and maximum) between the matched cases and controls by fractionation 
schedule was compared using paired t-tests. 
Both Ki67 endpoints were analysed as continuous variables to maximise 
statistical power [18]. Multivariable conditional logistic regression models were fitted 
to estimate the prognostic value of Ki67 on the risk of BCR, using the entire Trans-“ 
case-control study cohort. To determine whether Ki67 predicted BCR by 
fractionation, a biomarker-fractionation interaction term was included. Three 
comparisons were undertaken to avoid confounding by different recurrence rates 
across trial arms (74Gy/37f versus 60Gy/20f, 74y/37f versus 57Gy/19f and 60Gy/20f 
versus 57Gy/19f). Based on an alpha of 0.017, we estimated a power of 75.5%, 
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74.8% and 70.0% to detect an interaction between each fractionation schedule and 
Ki67 respectively (table S4).  
All statistical analysis was conducted using STATAv13.0 and R 
(version:i3863.3.3). 
Results 
Patient characteristics 
437 cases were assessed by both scoring investigators. Ki67 scores were 
provided by both investigators in 400 cases, in 37 cases there was insufficient 
tumour present. The final matched dataset comprised 173 patients with BCR after 
start of radiotherapy (cases) and 173 patients without recurrence (controls). 
Matching was achieved to 100% of relevant criteria in all cases analysed. 54 patients 
were excluded as they did not have an appropriate match, these were usually 
controls with no available matching case. Table 1 shows the distribution of the 
matching variables and age for the controls and cases.  
Agreement in Ki67 scores  
Of the total of 400 cases scored by both investigators, in 12 (3.0%) cases the 
difference in mean Ki67 between the two scoring investigators was ≥10% (IQR:11.8-
15.1%). These were re-scored by both scoring investigators. All re-scores were 
within the required <10% discrepancy.  
Scatter plots comparing each scoring investigator’s final scores, and Bland-
Altman plots comparing the difference in final score versus the mean Ki67 are shown 
in figure 2 (original scores figure S1). The Bland-Altman plots indicate that the 
difference in score tended to increase as the mean Ki67 score increased. The overall 
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agreement was considered to be good with a concordance correlation coefficient of 
0.74 (95% CI: 0.70-0.78, p<0.001) for the final scores. For the original scores prior to 
rescore, the concordance correlation coefficient was 0.63 (95% CI: 0.58-0.68, 
p<0.001). 
Prediction of biochemical/clinical recurrence  
Multivariable conditional logistic regression models using the entire Trans-“ 
case-control study sample showed that both mean Ki67 and maximum Ki67 were 
statistically significant predictors of BCR (tables 2 and S3). For each unit increase in 
mean Ki67 the odds of BCR is estimated to increase by 9% (OR=1.09, 95% CI: 1.04-
1.15, p=0.001) having adjusted for matching variables and age. It is clinically 
relevant that the prediction of recurrence by mean Ki67 is independent of Gleason 
grade. The lack of correlation between mean Ki67 and Gleason grade is also 
displayed in the box and whisker plot (figure 3). For the maximum Ki67, the odds of 
BCR were estimated to increase by 5% for each unit increase in the maximum Ki67 
score (OR=1.05, 95% CI: 1.01-1.09, p=0.006) in the multivariable model. 
Prediction of fraction sensitivity 
The interaction tests between either mean or maximum Ki67 and fractionation 
schedule was not statistically significant for all comparisons (table 3 and S3). The 
distribution of mean and maximum Ki67 scores according to fractionation schedule 
and recurrence status, including a statistical comparison of the difference between 
cases and controls within fractionation arms is shown in figure S2.  
Discussion 
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This study measures Ki67 staining indices in localised PCa treated with 
different radiotherapy fractionation schedules. It indicates that the global unweighted 
method for scoring Ki67 can be used with good agreement between independent 
scoring investigators without prior experience of this method. To our knowledge this 
is the first report using the global unweighted method in PCa. However it is an 
established method to aid treatment stratification in breast cancer [19] where Ki67 is 
used clinically to distinguish between low proliferation luminal A and higher 
proliferative luminal B breast cancer subtypes [20].  
The statistically significant association between mean Ki67 and prediction of 
BCR has potential clinical application. Our results require external validation in 
additional patient cohorts, with particular attention to the spectrum of Ki67 
expression in different risk groups and a rigorous assessment of scoring 
concordance in prostate biopsies across different centres. Patients with high mean 
Ki67 but otherwise lower risk factors could be recommended longer or more 
intensive androgen deprivation (ADT), with possible addition of Docetaxel or 
abiraterone [21]. Patients with low mean Ki67 could be reassured that they are likely 
to have a good prognosis and might be candidates for studies of reduced ADT. This 
study suggests that Ki67 is of maximal predictive benefit when used as a continuous 
variable, this method of stratification is used effectively in the clinic for Ki67, and 
other expression profiling-based algorithms [19,22].  
Our exclusion of patients with BCR less than two years after radiotherapy 
means the estimates of the predictive value of Ki67 are likely to be conservative. 
Maximum Ki67 was also a statistically significant predictor of BCR which is worthy of 
further study as a single field assessment of 100 cells is quicker than 4 fields for 
mean Ki67.  
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The apparent lack of interaction between Ki67 and fractionation schedule also 
has clinical implications. The range of proliferative indices seen indicates that, the 
predominantly intermediate risk, PCa included in the trial are usually slowly 
proliferative. However when including those cancers showing relatively high 
proliferation rates, there was no suggestion of a detriment using hypofractionated 
radiotherapy schedules giving 3Gy/fraction. Other tumour types encompass wider 
ranges in proliferation and show higher average proliferation [7]. Our results should 
not be interpreted as demonstrating a general lack of association between 
proliferation and fraction sensitivity. An important confounding factor may be the 
complex interplay between fraction sensitivity and overall treatment time [23]. 
Additionally we acknowledge that the statistical power of tests of interaction are low, 
and that a relatively small proportion of high risk PCa were included in ”. 
3112 of 3216 (96.7%) of patients recruited to “ were treated with ADT from 
just after their diagnostic biopsy until completion of radiotherapy. ADT may modulate 
fraction sensitivity as it can markedly reduce proliferation and affect repair of double 
stranded DNA breaks (dsDNA) [24]. ADT can also inhibit the cell cycle at the G1/S 
checkpoint as part of induction of senescence [25,26]. This inhibition could restrict 
use of dsDNA repair pathway homologous recombination, which operates 
exclusively in S and G2 and is thought to mediate resistance to fraction sensitivity 
[27,28]. Cells would instead rely on error prone non-homologous end joining which 
operates throughout the cell cycle and is important for fraction sensitivity [27,28]. In 
the PROFIT trial of radiotherapy fractionation, men did not receive ADT and 
outcomes were similar to “ [29]. This suggests that ADT does not have a major 
impact on average fraction sensitivity in PCa, however ADT may have confounded 
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the interaction between proliferation and BCR according to fractionation schedule in 
our study.   
Our results are supported by a recent report by Pollack et al [30]. In this, a 
single cut-point (11.3%) was used to score Ki67, fractionation schedules differed to 
our study and there were fewer failure events. However Ki67 demonstrated 
independent prediction of prognosis and did not predict fraction sensitivity. It is 
relevant that Ki67 immunohistochemistry is routinely available and affordable for 
most pathology laboratories, and automated scoring algorithms are showing 
potential clinical applicability [31].  
This study assessing Ki67 in patients treated with different radiotherapy 
fractionation schedules reaches two conclusions. Firstly, it does not suggest that 
there is a detriment to using hypofractionated radiotherapy schedules in PCa 
showing relatively high proliferation. Secondly, Ki67 is a highly statistically significant 
biomarker predicting recurrence, independent of established prognostic factors. As 
localised PCa shows diverse clinical outcomes, Ki67 has a potential clinical 
application to guide treatment stratification. 
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Figure 1: Scoring Ki67 using the global unweighted methoda.  
aThis case contained 50% high proliferation tumour and 50% low proliferation tumour 
therefore high power fields were selected for 2 highly proliferative areas and 2 low 
proliferative areas. In this case the number of positive staining cells were: field 1 
39/100, field 2 33/100, field 3 5/100 and field 4 5/100. This gives a mean Ki67 score 
of 20.5% and a maximum Ki67 score of 39%. 
Figure 2: A: Scatterplot showing concordance in final mean Ki67 between 
independent scoring investigators, B: Brand-Altman plot showing difference in final 
scores between investigator 1 and investigator 2 versus means scores. 
Figure 3: Box and whisker plot showing relationship between Mean Ki67 and 
Gleason grade group.  
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Table 1. Distribution of the matching variables and age by fractionation schedules.  
 
 
% % %
PSA
<10 29.3 38.5 52.4
10- & <20 63.8 51.9 41.3
20- 6.9 9.6 6.3
T1 19.0 15.4 31.7
T2 72.4 73.1 55.6
T3 8.6 11.5 12.7
≤ 6 10.3 9.6 12.7
3+4 53.4 57.7 47.6
4+3 27.6 19.2 23.8
≥ 8 8.6 13.5 15.9
60Gy (N = 104, 30.1 %) 57Gy (N = 126, 36.4 %)74Gy (N = 116, 33.5 %)
PSA 
70.1 (6.1)
Median (IQR)
9.6 (7.3-13.0)
Mean (SD)
68.4 (6.2)
Median (IQR)
9.7 (7.2-15.0)
Median (IQR)
12.2 (8.6-15.1)
Mean (SD)
68.0 (5.8)
Median (IQR)
11.6 (8.6-18.1)
Median (IQR)
12 (8.9-15.8)
Mean (SD)
69.8 (6.6)
Median (IQR)
11.9 (9.1-16.2)
8
30
15
10
Age at 
randomisation 
(years)
Mean (SD)
69.4 (6.3)
Mean (SD)
68.9 (5.4)
Mean (SD)
10
Cases (N = 63)
N
33
4
20
35
8
35
8
8
30
15
30
10
7
Controls (N = 63)
N
33
26
4
20
7
Cases (N = 52)
N
20
27
5
8
38
6
5
38
6
5
30
10
N
20
27
5
8
42
5
6
31
16
5
5
6
31
16
5
N
17
37
4
11
26
N
17
37
4
11
42
Tumour stage
Gleason Score
Controls (N = 58) Cases (N = 58) Controls (N = 52)
Table 1
 Table 2: Odds ratio for BCR estimated by multivariable conditional logistic regression 
models (n=346) using Ki67 as a continuous variable, for mean and maximum Ki67.  
Ki67  
Biomarker    OR* 95 % CI P value 
mean Ki67 scores 
  
1.09 1.04 - 1.15 0.001 
max Ki67 scores 
  
1.05 1.01 - 1.09 0.006 
*Odds ratios (OR) are adjusted for the matching variables and age at randomisation. 
Table 2
 Table 3: Odds ratio for BCR estimated from multivariable conditional logistic 
regression models without and with interaction terms between the mean Ki67 scores 
and fractionation schedules. 
Schedules Variable OR 95 % CI (OR) 
P value 
(OR) 
P value for 
interaction* 
74 Gy & 60 Gy mean Ki67 1.09 1.02 – 1.17 0.007 0.26 
74 Gy & 57 Gy mean Ki67 1.07 1.01 – 1.14 0.03 0.59 
60 Gy & 57 Gy mean Ki67 1.11 1.04 – 1.19 0.001 0.59 
OR’s are adjusted for matching variables and age at randomisation. *P value for the interaction 
between the mean Ki67 scores and fractionation schedules. 
 
 
Table 3
Figure 1: Scoring Ki67 using the global unweighted methoda.  
aThis case contained 50% high proliferation tumour and 50% low proliferation tumour therefore high power fields were selected for 2 highly 
proliferative areas and 2 low proliferative areas. In this case the number of positive staining cells were: field 1 39/100, field 2 33/100, field 3 
5/100 and field 4 5/100. This gives a mean Ki67 score of 20.5% and a maximum Ki67 score of 39%. 
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Figure 2: A: Scatterplot showing concordance in final mean Ki67 between independent scoring investigators, B: Brand-Altman plot 
showing difference in final scores between investigator 1 and investigator 2 versus means scores. 
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Figure 3: Box and whisker plot showing relationship between Mean Ki67 and Gleason grade group.  
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